After completion of a number of large scale Genome-Wide Association Studies (GWAS), there is still a significant amount of trait and disease variance that cannot be explained by existing genetic variability. This review introduces new, Integrative Network-based Association Study (INAS) approaches that aim to minimize the impact from multiple hypothesis testing statistics, thus allowing the identification of rare variants/alterations and epistatic interactions. In particular we discuss methods that rely on the de novo computational, experimental, and integrative dissection of context specific molecular interaction networks (or interactomes, for short). We provide several examples of how these approaches may be used to tackle discovery of genetic variants and somatic alterations causally related to the presentation of specific traits and diseases. We also discuss how more complex systems, including a variety of non-cell-autonomous traits and diseases will require new multicellular networks that explicitly represent short distance paracrine and long distance endocrine interactions.
Introduction
Over the last ten years, the genome wide study of both heritable and somatic human variability has gone from a theoretical concept to a broadly implemented, practical reality, covering the entire spectrum of human diseases: from cancer to obesity to neurodegenerative disorders. While a number of exciting findings have emerged from these studies 1 , the result of such genome wide association studies (GWAS) has been for the most part sobering. For instance, although several genes displaying medium to high penetrance within heritable traits have been inferred by these approaches for certain conditions, other diseases are still missing identification of much of the genetic risk [2] [3] [4] [5] [6] [7] , and few epistatic interactions or low penetrance genes have been identified due to impractical requirements for cohort sizes 8 as well as a lack of methodological developments that maximize power for such detections 9 . At the other end of the spectrum, the extensive somatic genomic rearrangements observed in solid tumors 10 yield such a broad range of candidate alterations that distinguishing 'driver' from 'passenger' alterations is difficult.
This begs the question of whether, in a post-GWAS era, existing GWAS datasets may still hold a trove of hidden value. It has been suggested, for instance, that GWAS data could be more insightful when studied integratively within the context of other data modalities. Indeed, a number of previous studies have integrated significant genotypephenotype associations with databases of gene annotations, such as the Gene Ontology 11 , MSigDB 12 , or the Kyoto Encyclopedia of Genes and Genomes 13 . The goal of these studies is to recognize higher-order structure within the data through aggregation of loci that encode genes with similar functions or that are in the same pathway.
A particularly important framework for the integration of genomic, metabonomic, and proteomic data is provided by the context-specific networks of molecular interactions that determine cell behavior. The basic hypothesis is straightforward. Among the entire spectrum of genetic and epigenetic variants, those contributing to a specific trait or disease must have some broad coalescent properties, allowing their effect to be functionally canalized via the cell regulatory machinery or via the cell-communication machinery that allows distinct cell types to interact. Thus, if a comprehensive and accurate map of all intra and inter-cellular molecular interactions were available, then genetic and epigenetic events implicated in a specific trait or disease should cluster within sets of closely interacting genes, within the cell's regulatory network.
Two approaches are then possible. First, if the regulatory networks determining the cell pathophysiological behavior were known a priori, e.g. a canonical cancer or functional pathway, one could systematically reduce the number of statistical tests for association between genetic or epigenetic variations and the trait or disease of interest by considering only events that form significant clusters within regulatory networks. This is because events that are closer in the regulatory topology of the cell are more likely to produce related phenotypic effects. Such a Pathway-Wide Association Study (PWAS) strategy 14 may improve our ability to distinguish signals from background noise by mitigating the magnitude of the multiple hypothesis testing correction. In most cases, unfortunately, the set of molecular interactions or pathways necessary to present a trait or a disease-related phenotype are not well characterized at the molecular level. Indeed the entire classical notion of relatively linear and interpretable disease pathways may need to be revisited in light of the dynamic, multi-scale, and context-specific complexity of gene regulatory networks. Thus, a second approach requires the simultaneous reconstruction of both context-specific (and possibly multi-cell) gene regulatory networks and of the genetic and epigenetic events they harbor. We shall call this second strategy Integrative Network-based Association Studies or INAS and suggest that INAS will become increasingly dominant as the dynamic and cell-context specific nature of gene regulatory networks is further elucidated.
In this perspective, we explore current advances in PWAS and INAS research, the natural corollaries of a regulatory-network-oriented view of traits and disease, and future directions that are being pursued within the emerging community of Systems Genetics.
We will explore how networks (and pathway motifs within them) can be reconstructed and validated and how they may provide a valuable integrative framework to interpret GWAS as well as other genetic and epigenetic variability data.
THIS IS NOT MY BEAUTIFUL PATHWAY
An increasing body of evidence suggests that canonical pathways may be woefully inadequate to represent and model the complex interplay of signal transduction, transcriptional, post-transcriptional, metabolic, and other regulatory events that ultimately determines cellular behavior. Rather, they satisfy our need to interpret biological phenomena as linear chains of events or other simple pathway models that can be easily visually interpreted. Unfortunately, this is a dramatic oversimplification. Biological processes and their regulatory control are anything but linear and cellular processes are determined by complex, multivariate interactions that cannot be visually interpreted.
Both require the power of computational modeling to yield valuable biological insight.
For instance, it has been shown that individual transcription factors regulate hundreds to thousands of highly cell-context dependent target genes. Indeed, functional specificity is achieved opportunistically by combinatorial interactions between multiple transcription factors. For instance, while FOXM1 and MYB individually regulate transcription of more than a thousand distinct genes, the about roughly 100 targets they co-regulate are exquisitely specific to human B cells during germinal center formation, see Fig. 1a .
Conversely, those regulated by either one independently have a wide range of functions and are not specifically differentially expressed 15 . Similarly, transcription factor activity is modulated by hundreds of signal transduction proteins 16 , whose availability is again context specific. As discussed, such intrinsic complexity is made even more Whereas cancer may make a reasonably good cell autonomous system (given when you profile cancer you get both stroma and cancer at the same time), common non-cancer human diseases like obesity and type II diabetes can result from a failure in multiple organ systems including the central nervous system and tissues involved in partitioning and disposal of nutrients, and so may be best modeled as a non-cell autonomous system.
In fact, we have shown that interaction networks constructed between tissues like hypothalamus and adipose tissue collected from an experimental cross population segregating obesity and type II diabetes, may be specific to cross tissue interactions 28 .
That is, some subnetworks identified in cross-tissue interaction networks are not visible within single tissue networks, exhibiting a degree of regulation that may go beyond simple cell autonomous systems. Molecular networks constructed from heterogeneous tissues have also exhibited extraordinary context sensitivity, with interactions among different cell types making up a given organ specific to functions associated with that organ. In a model for type II diabetes, molecular interactions between different tissues were observed to be more abundant than interactions within any given tissue (or cell type) 29 , and insulin signaling in osteoblasts has been shown to be necessary for wholebody glucose homeostasis 30 . These examples highlight that molecular networks capable of predicting whole system behavior will require modeling approaches that go beyond cellular networks, requiring the explicit representation of interactions at a hierarchy of scales that provide a path to define the molecular interactions that define physiological states related to disease phenotypes 31 .
REVERSE ENGINEERING CELLULAR NETWORKS
Just a few years ago, determining and experimentally validating a single kinase substrate or transcription factor target required a year or more of bench work. Since regulatory and protein-complex networks in eukaryotes appear to be highly complex -hundreds of thousands of interactions, -context-specific 34 , and dynamic, how can one possibly reconstruct them in sufficient depth and with sufficient accuracy? Indeed, imagine having not only to elucidate hundreds of thousands of these interactions but also having to assess how they may change and reorganize themselves, under multivariate control, within distinct cellular phenotypes and possibly under distinct stimuli. It is precisely out of this necessity that the fields of high-throughput computational and experimental reverse engineering have blossomed. This is an important and timely effort. Ultimately, our success in elucidating disease related mechanisms on a rational, predictive basis will depend on our ability to use stochastic and kinetic models to accurately map cell regulatory networks and to predict their response to pathophysiological stimuli.
On the experimental side, large-scale, high-throughput efforts have started to release enormous amounts of raw data over the last five years. These data can be used as a scaffold for the assembly of entire regulatory and protein-complex networks, thus providing insight into the architecture of the cell in terms of how direct interactions between molecules may allow assembly of protein complexes, transduction of signals, and control of the transcriptional machinery of the cell 37 . For example, networks of protein-protein interactions in human cells have been assembled using yeast two-hybrid (Y2H) technology or tandem affinity purification coupled with mass spectrometry (TAP-MS) 20 . Similarly, candidate transcriptional targets of specific transcription factors (protein-DNA interactions) have been mapped using the techniques of chromatin immunoprecipitation coupled with DNA microchips (ChIP-chip) 38 or sequencing (ChIP-PET) 39 , DNA adenine methylase identification (DamID) 40 , or yeast one-hybrid assays 41 .
Physical interactions can also be measured in vitro using DNA or protein arrays, which have been used to identify transcription factor binding sites and the substrates of kinases 44 . While interactions characterized by high-throughput experimental methods generally have high false positives and false negative rates and are unlikely to generalize to cellular contexts other than the one in which they were ascertained, they nonetheless provide an initial if sparse snapshot of regulatory networks, especially when integrated with other types of data that can help filter the interactions most appropriate to a given context 25 . By mapping and interpreting changes among snapshots in different contexts we can begin to create a more comprehensive scaffold.
Complementing and extending high-throughput experimental assays, computational reverse-engineering algorithms have recently achieved accuracy and sensitivity comparable with their experimental counterpart, at a fraction of their cost and time requirements. Computational methods for reverse-engineering cellular networks were first developed for the study of prokaryotes and lower eukaryotes [45] [46] [47] and have more recently become highly successful in reconstructing the transcriptional 
EXAMPLES OF PWAS AND NBAS APPROACHES
In the following, we discuss several approaches that have been successful in identifying genes that are critically involved in the presentation of a phenotype, due to either genetic alteration or functional dysregulation. This list, rather than being comprehensive, is intended to illustrate different approaches in both PWAS and NBAS . These included several genes in the BCR and other signal transduction pathways, such as CARD11, A20, TRAF2, TRAF5, TAK1, and RANK, among others. Surprisingly, while Nf-κB itself was not genetically altered in the ABC subtype, it was shown to constitute a key non-oncogene addiction for ABC-DLBCL cells.
Canonical
There have also been attempts to create more informative pathways by automated data-mining of literature data, using machine-learning approaches. These more complex and non human-interpretable networks have been used to cluster information coming from disease-related human variability data, such as for instance in the study of genetic predisposition to several human diseases 72 .
Integrative genomics: There is already a rich literature on methods for using cellular networks, including protein-protein and protein-DNA interaction networks, to interpret gene expression profiles, with the goal of identifying network "hot spots" or "expression- diabetes phenotype, where genetic loci in this population associated with t2d were very strongly enriched for associating with genes in this network. The integration of these data were then used to show that over half of the genes in this population supported as causal for t2d were located in this single subnetwork. SNPs in human populations that were associated with the genes comprising this mouse-derived t2d network were then observed to be greater than 8 times enriched for SNPs that associate with t2d in GWAS (one of the most striking pathway enrichments published to date for a common human disease). Interestingly, no similar enrichments were observed in using known pathways defined in the GO and KEGG databases (Zhong et al. AJHG paper).
Along similar lines, module networks approaches 45 were extended to identify genetic determinants of genetic module differential regulation . These observations suggest yet another approach to NBAS, based on the identification of the regulatory modules that control the disease subtype signatures followed by interrogations of pathways directly upstream of these modules as well as by association of genetic alterations in the tissue sample with the activity of these modules, for instance using the mutual information, , between the presence of a specific alteration A x and module activity M. These types of approaches may significantly reduce the number of hypotheses that may need to be tested and increase the specificity of the molecular link from alteration→cellular-phenotype to alteration→molecular-phenotype, the latter being far less prone to assessment errors.
A NEED TO REVIEW HOW WE WORK TOGETHER
The power to build better maps of disease in the post-GWAS era clearly leverages emerging "omics" technologies that will benefit from collecting data from large samples of patients over multiple intervals of time. Most of the historic studies that drive our current understanding of diseases have been performed by single institutions often with the primary goal of taking data to build models that are then communicated as the results and conclusions conveyed by citable scientific articles. This current process does not assume that most data might be more useful if it could be accessed by others to build further models and hypotheses, beyond those envisioned by the original scientist. In fact, the absence of a culture of appropriate data sharing in the life and biomedical sciences is perhaps the single greatest impediment to the rapid development of the integrative techniques described above. For instance, GWAS data will no longer be sufficient in isolation to understand the complexity of disease and how best to predict and treat it, but instead will need to be paired with additional molecular profile data as well as with data that may be used to dissect the underlying regulatory model for the specific cellular context of interest.
Even though genomic data is robust and may be successfully used across a wide range of analyses, most investigators involved in clinical genomic studies hold the data hostage for fear of missing out on the opportunity to extract the last bit of publishable value from it. The net result is that 80% of data is never published and more importantly never shared. The cultural barriers to evolving data sharing involve re-examining current reward structures for career advancement and peer recognition that are based on being a first or last author, and the need to own intellectual property around biologic insights. We need to transition to a workplace where scientists are rewarded for their insights, such as the proposing of new disease models, so that they can occur much earlier in the process of working with clinical/genomic data sets.
One example of piloting the advantages of sharing data, models, and tools is called "The Federation". In the summer of 2010 five groups: Sage Bionetworks, the Butte lab, the Califano lab, the Ideker lab, and the Schadt lab decided to test the mechanics of data sharing by jointly working on projects in aging, diabetes, and cancer based on predefined rules on data access and data sharing. Federation rules imply that anyone interested in data, tools, and models produced by any of the five groups would have access to these pooled resources and would implicitly respect publication rights by including data producers in their manuscripts and by notifying each other of pending manuscripts using this data. More importantly, it was set up so that disease models would be built by teams dynamically formed for the projects in an environment usually only
seen for "open source" software projects. Multiple early experiments such as The Federation will be needed to aid in the development of the type of governance rules and processes required to facilitate the sharing in a laboratory environment needed to build the generative disease maps possible in the NBAS and PWAS worlds that follow the large national scale effort in GWAS.
Conclusions
Regulatory networks are emerging as powerful integrative frameworks to understand and interpret the role of genetics and epigenetics in disease predisposition and etiology. By providing the backbone of molecular interactions through which signals are transduced and gene expression is regulated, they dramatically limit the search space of allele variants and alterations that can be causally linked to the presentation of a phenotype. In addition, by providing accurate regulatory models of the cellular machinery that integrates signals that are dysregulated in disease, they yield valuable hypotheses for diagnostic and prognostic biomarkers, for therapeutic targets, and for the understanding of context-specific synthetic lethality.
For regulatory networks to yield their full potential, however, we must understand their variability across cellular context, their dependence on the genetic and epigenetic layer, and their dynamics over time. The latter is particularly important for diseases where the underlying cellular pathophysiology cannot be considered to be close to steady state, such as metabolic and neurological diseases.
Surprisingly, even rough regulatory models that are largely inaccurate and incomplete are starting to show significant value in dissecting the genetics of disease.
Thus, we expect that as these models progress and become better able to deal with the dynamic, cell context-specific nature of biological process regulation, they will dramatically increase their ability to yield key insight into both normal cell physiology and its dysregulation in disease. We herald network reverse-engineering and interrogation as one of the most critical challenges of quantitative biology.
